🔗 Share this article The United States and United Kingdom Reach No-Tariff Deal on Medicines. Stock image of drug trade. Britain and America have reached a significant bilateral deal that will preserve no levies on British medicine shipments going into the American market. Key Provisions of the Pact In exchange for the tariff guarantee, the UK has pledged to boost spending on drugs through the NHS. This move guarantees that duties on these vital products will be held at zero for a period of the next three years. This deal comes after previous threats to hike import taxes on patented drug imports, with increases floated up to 100%. "This agreement with the United Kingdom bolsters the international landscape for innovative medicines and introduces long-overdue equity to transatlantic medicine commerce," a release noted. Commercial Impact Pharmaceuticals are one of the Britain's most significant export categories to the United States, which is clearly the primary destination for large companies like GSK and AstraZeneca. Export figures reveal that in the 12 months to the end of the third quarter, the UK shipped drugs totaling £11.1bn to the US. This figure accounted for 17.4% of British export trade in that period. "This guarantee protects employment, stimulates funding and sets the stage for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented. Detailed UK Commitments The agreement includes several specific pledges from the British government: Price Threshold Increase: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by twenty-five percent. Boosted Medicine Funding: There is a goal to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period. Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. Last year, repayments exceeded twenty percent. Broader Context The deal follows a ongoing dispute between the drug companies and the UK government over drug pricing and NHS adoption. The disagreement were exacerbated by claims that US customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU. Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been directed toward American operations. The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
Stock image of drug trade. Britain and America have reached a significant bilateral deal that will preserve no levies on British medicine shipments going into the American market. Key Provisions of the Pact In exchange for the tariff guarantee, the UK has pledged to boost spending on drugs through the NHS. This move guarantees that duties on these vital products will be held at zero for a period of the next three years. This deal comes after previous threats to hike import taxes on patented drug imports, with increases floated up to 100%. "This agreement with the United Kingdom bolsters the international landscape for innovative medicines and introduces long-overdue equity to transatlantic medicine commerce," a release noted. Commercial Impact Pharmaceuticals are one of the Britain's most significant export categories to the United States, which is clearly the primary destination for large companies like GSK and AstraZeneca. Export figures reveal that in the 12 months to the end of the third quarter, the UK shipped drugs totaling £11.1bn to the US. This figure accounted for 17.4% of British export trade in that period. "This guarantee protects employment, stimulates funding and sets the stage for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented. Detailed UK Commitments The agreement includes several specific pledges from the British government: Price Threshold Increase: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by twenty-five percent. Boosted Medicine Funding: There is a goal to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period. Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. Last year, repayments exceeded twenty percent. Broader Context The deal follows a ongoing dispute between the drug companies and the UK government over drug pricing and NHS adoption. The disagreement were exacerbated by claims that US customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU. Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been directed toward American operations. The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.